---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025167"
form_type: "8-K"
ticker: null
cik: "0001733413"
company_name: "TFF Pharmaceuticals, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:08:44.367602+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TFF Pharmaceuticals raises ~$1.2M in registered direct offering with warrants at $8.00/share

## Summary
- Sold 147,500 shares at $8.00 in registered direct offering; gross proceeds ~$1.2M.
- Concurrent private placement of warrants to purchase 147,500 shares at $8.00; exercisable for 5.5 years.
- H.C. Wainwright acted as sole placement agent; receives 7% cash fee and 10,325 warrants at $10.00.
- Net proceeds to be used for working capital and general corporate purposes.
- Closing occurred March 22, 2024; offering priced at-the-market under Nasdaq rules.

## SEC filing metadata
- accession: 0001213900-24-025167
- form_type: 8-K
- cik: 0001733413
- company_name: TFF Pharmaceuticals, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/ea0202366-8k_tffpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025167
- JSON: https://secwatch.observer/filing/0001213900-24-025167.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025167.txt

## Key facts
- Material Agreements
  TFF Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  source text: In connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm
- Material Agreements
  TFF Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.2 million (effective 2024-03-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $1.2 million
  - Effective: 2024-03-20
  source text: On March 20, 2024, TFF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market (the “Registered Offering”), an aggregate of 147,500 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $8.00 per share (the “Shares”), for gross proceeds from the Registered Offering of approximately $1.2 million, before deducting the placement agent fee and estimated offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.